Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
PCSK9 drugs
Biotech
Beam offloads Verve rights to Lilly for up to $600M
Beam Therapeutics is selling off opt-in rights to Verve's cardio work to Eli Lilly for up to $600 million.
Max Bayer
Oct 31, 2023 6:00am
LIB's cholesterol-busting drug hits goal in 2nd phase 3 trial
Aug 29, 2023 6:30am
Merck bets big on oral PCSK9 inhibitor with phase 3 program
Aug 25, 2023 8:35am
Cholesterol-focused Esperion loses appetite for Serometrix pact
Aug 1, 2023 10:46am
Merck cardio plan forms as sotatercept, PCSK9 inhibitor impress
Mar 6, 2023 12:00pm
Junshi data tee up challenge to Amgen, Sanofi in growth market
Feb 28, 2023 2:00am